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There is growing interest in using natural substances from plants to potentially enhance anticancer 
activity. A key target in this respect is natural killer (NK) cells in order to generate an anticancer-
immune response. Luteolin used in this study was derived from a local plant Brucea javanica leaves 
extract; through a bioassay-guided fractionation. The expression of interleukin-2 (IL-2) and interferon-γ 
(IFN-γ) was increased after 20 h treatment of 0.1 µM luteolin in human mixed lymphocytes, which 
reflects the activation of NK cells. This was further confirmed in co-culture experiments. NK cell-
induced K562 target cell death was increased in the presence of luteolin. These results show that 
luteolin activates NK cells to kill target cells indicating the potential use of luteolin as an anticancer 
immunostimulant.  
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INTRODUCTION 
 
Immunotherapeutic agents have become an important 
addition to the list of anticancer treatments. Some types 
of natural products have the ability to stimulate the 
immune system such as a potent stimulator of natural 
killer (NK) cells (Abuharfeil et al., 2000; Amino et al., 
1983; Toliopoulos et al., 2012). NK cells are one of the 
components of the innate immune system which have the 
ability to directly kill the malignant, damaged and virally 
infected cells, by the release of perforin and granzyme 
(Geller and Miller, 2011).  Activated  NK  cells  are  potent 
anti-tumor effector cells and play an important role in 
immunosurveillance (Rabinowich et al., 1991). The lytic 
activity of NK cells can be augmented by exposure to 
interferons (Kuribayashi et al., 1981) and interleukin-2 
(IL-2) (Devos et al., 1984).   
Brucea javanica (L.) Merr. is a shrub from family 
Simaroubaceae and it is known as ‘lada pahit’ among 
Malaysian due to its bitter taste. Compounds from B. 
javanica have been shown to have various biological 
activities such as cytotoxic and antileukemic (Anderson et  
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al., 1991; Luyengi et al., 1996).
 
Luteolin belongs to 
flavones type (flavonoids) of polyphenolic group of 
compounds. Epidemiological studies have consistently 
shown that flavonoids might play a prominent role in 
cancer prevention, since these compounds are found in 
numerous plants that are associated with a reduced 
cancer rate (Birt et al., 2001). However, very little 
information is available on the ability of these compounds 
to modulate anticancer immune activities. Thus, in this 
present study we have evaluated the effects of luteolin on 
NK cell responses which are known to modulate target-
cell killing activity. 
 
 
MATERIALS AND METHODS 
 
Cell culture 
 
K562 target cells were purchased from American Type Cell Culture 
 (ATCC) and maintained in a humidified atmosphere of 5% CO2 
incubator at 37°C. All culturing work was handled using sterile 
techniques.  
 
 
Measurement of cytokine production 
 
The effects of luteolin on the expression of IL-2 and interferon-γ 
(IFN-γ) were measured via Enzyme-Linked Immunosorbent Assay 
(ELISA). 0.1 µg/ml of phytohemagglutinin (PHA) was used as a 
stimulator because it can stimulate an increase in both IL-2 and 
IFN-γ production. The range of concentrations of luteolin used was 
0 to 100 µM and the cells were incubated for 24 h. The level of IL-2 
and IFN-γ were measured from the medium (supernatant) of the 
mixed lymphocytes culture. The experiment was carried out 
according to the manufacturer’s protocol (BioSource CytoSetTM, 
Invitrogen).  
 
 
Magnetic cell separation 
 
The isolation of NK cells was achieved using a human 
CD56+CD8+/CD8ˉ NK cell isolation kit from Miltenyi Biotec, 
according to the manufacturer’s protocol. Briefly, lymphocytes were 
isolated from human peripheral blood mononuclear cells (PBMCs), 
and were magnetically labelled with a cocktail of biotin-conjugated 
antibodies against lineage-specific antigens and a cocktail of 
MicroBeads. Upon subsequent magnetic separations of cells over a 
MACS® Column (LS Column) that was placed in a magnetic field of 
a MACS Separator, the magnetically labelled non-NK cells (T cells, 
B cells and other debris) were retained within the column, while the 
unlabelled (untouched) NK cells were eluted.  
 
 
NK cell target-cell killing assay 
 
The NK cells were cultured together with the human myeloid 
leukaemia K562 cells, in Eppendorf tubes for 3 h (37°C, 5% CO2, 
100% humidity). The best concentration of luteolin that enhanced 
the production of IL-2 in mixed lymphocytes was used in the co-
culture assay. After 3 h, cells were washed with phosphate buffered 
saline (PBS) and then blocked with 5% mouse serum in PBS  for 10  
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min at room temperature (RT). Cells were washed again and 
stained with 20 µl of anti-CD56 FITC-labelled antibody for each 
tube, then incubated at RT. After 15 min, the cells were washed 
and 5 µl of 7-aminoactinomycin D (7-AAD) was added, then 
incubated for 10 min at RT. The cells were then washed and 
resuspended in 200 µl of PBS. The percentage of K562 cell death 
was determined by flow cytometric analysis. BD fluorescence-
activated cell sorting (FACS) Diva software was used to evaluate 
the 7-AAD staining to indicate non-viable K562 cells and was gated 
specifically to exclude the fluorescein isothiocyanate (FITC, CD56+) 
labelled cells. 
 
 
RESULTS AND DISCUSSION 
 
Effects of luteolin on NK cells regulatory cytokine 
production 
 
Figure 1 shows the effect of luteolin on cells regulatory 
cytokine production. 
 
 
Effects of luteolin on activation of NK cell and 
anticancer immune response 
 
The percentage of K562 cell death was found to be 
increased in the presence of both NK cells and luteolin as 
compared to cultures of K562 with NK cells or luteolin 
alone (Figure 2). 
The removal of cancer cells by the host immune 
response has long been considered as the most 
advantageous anticancer strategy. This is because our 
immune systems have highly specific recognition 
mechanism which would potentially eradicate cancerous 
cells with the least damage to normal cells (Wahle et al., 
2010). The enhancement of immune cell responses that 
can specifically target cancer cells could prove to be very 
effective for prevention and treatment strategies. 
Therefore, any agents that enhance anti-tumour effector 
cell activities have naturally been perceived as an ideal 
mechanism in cancer treatment and prevention (Wahle et 
al., 2010). 
In this study, luteolin was demonstrated to activate NK 
cells. Luteolin stimulated an increased production of both 
IL-2 expression and IFNγ. An enhancement of the killing 
of K562 leukemic cells was also shown. Direct evidence 
for NK cell targeting of human cancer came from studies 
of NK cell interactions with primary tumour cells tested for 
susceptibility to NK cell-mediated lysis ex-vivo. Such 
approaches have been taken for neuroblastoma, ovarian 
carcinoma and multiple myeloma (Carlsten et al., 2007; 
Castriconi et al., 2004; El-Sherbiny et al., 2007). 
Previously, luteolin was found to induce apoptosis and 
cell cycle arrest in various cancer cells through the up-
regulation of pro-apoptotic proteins (Chang et al., 2005; 
Cheng et al., 2005).  
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Figure 1. (A) A significant increase of IL-2 was observed at 0.1 µM of luteolin. 
(B) The expression of IFN-y was increased by dose-dependent manner until 
the concentration of luteolin reach 1.0 µM. The IFN-γ level started to decrease 
when the luteolin was higher than 1.0 µM. The cytokine level was determined 
using ELISA methods and expressed as mean ± standard error of mean 
(SEM) of three separated experiment (P<0.05). 
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Figure 2. Percentage of K562 cell death after various types of treatment. ‘Lu’ 
is for luteolin. The percentages were calculated based on the positive control 
of 100% K562 cell death count. Percentage of dead cells was analysed using 
Fluorescence-activated cell sorting (FACS) Diva Software Analysis.  
 
 
 
 
However, the effect of luteolin on NK cell stimulation in 
this study has limitations, because there are many more 
factors that must be considered; which are recommended 
for future study. NK cells can kill cancer cells either by 
lysis or apoptosis. In lysis process, the perforin and 
granzyme was secreted by NK cells, which can create 
pores on the target cell’s membrane and leads to lysis of 
target cells. On the other hand, death receptor pathway 
of apoptosis is triggered when the Fas ligand on the 
surface of NK cells bind to Fas molecules on the surface 
of target cells (Vivier et al., 2012). Therefore, further 
studies are still needed, considering other factors such as 
evaluation other cytokines expression, the use of other 
stimulators for NK cells, type of cell death occurred in 
K562, as well as the expression of NF-ĸB transcription 
factor, perforin, granzyme and comparison between NK 
cells from healthy individuals and cancer patients. 
 
 
Conclusion 
 
Evidence in the literatures suggest that plant-derived 
medicines influence important biological effects on the 
immune system. Identification of such immunomodulatory 
properties in luteolin will be crucial in the discovery of 
novel, clinically relevant compounds for enhancing 
existing immunotherapy for cancer. Taken together, the 
therapeutic activity of luteolin holds the potential to be a 
safer anticancer treatment in the future. 
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